{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:54:58Z","timestamp":1787014498818,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,5,17]],"date-time":"2005-05-17T00:00:00Z","timestamp":1116288000000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    Immunotherapy (IT) with modified allergens reduces allergic rhinitis (AR) symptoms and medications requirements. Improvement of quality of life (QOL) is a key point in the treatment of AR. The aim of this study was to provide evidence of changes related to the patient's QOL (well\u2010being) induced by a modified (depigmented glutaraldehyde\u2010polymerized) therapeutic vaccine and of its safety.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Material and Methods<\/jats:bold>\n                    Fifty\u2010three patients with a well\u2010documented clinical history of seasonal AR sensitized to\n                    <jats:italic>Dactylis glomerata<\/jats:italic>\n                    and\n                    <jats:italic>Olea europaea<\/jats:italic>\n                    pollens were included in a randomized clinical trial. Twenty\u2010five patients (Group\u2010A) received a mixture of\n                    <jats:italic>D. glomerata<\/jats:italic>\n                    and\n                    <jats:italic>O. europaea<\/jats:italic>\n                    pollen extracts and 28 patients received placebo (group\u2010C). Any adverse event was recorded and graded in accordance with EAACI guidelines. RQLQ was recorded before the treatment (pollen season 2000) and after 1 year of treatment (pollen season 2001). Dose\u2013response skin prick test with each allergen extract was conducted at baseline and at the end of the study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    Each patient received 17 injections during this period. All patients completed the trial and no systemic adverse reactions were recorded. Symptom scores (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001) and medication requirements (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001) were significantly reduced in the IT group during the pollen season. This patient group also experienced greater and statistically significant improvement in overall RQLQ score and in five of the seven domains, all of them surpassing the threshold of \u2018minimal important difference\u2019 of 0.5 points.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    Results of this study provided evidence that IT with depigmented, glutaraldehyde\u2010modified allergen extracts was well\u2010tolerated and added beneficial effects to AR treatment in pollen allergic patients eliciting an improvement in QOL enough to justify a change in the patient's treatment.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2222.2005.02245.x","type":"journal-article","created":{"date-parts":[[2005,5,17]],"date-time":"2005-05-17T06:46:39Z","timestamp":1116312399000},"page":"572-578","source":"Crossref","is-referenced-by-count":40,"title":["Immunotherapy with depigmented glutaraldehyde\u2010polymerized extracts: changes in quality of life"],"prefix":"10.1111","volume":"35","author":[{"given":"E.","family":"Alvarez\u2010Cuesta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Aragoneses\u2010Gilsanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mart\u00edn\u2010Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Berges\u2010Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gonzalez\u2010Mancebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cuesta\u2010Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,5,17]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62850-5"},{"key":"e_1_2_9_3_2","first-page":"7","article-title":"The impact of allergic rhinitis on quality of life and other airway diseases","volume":"41","author":"Canonica GW","year":"1998","journal-title":"summary of a European conference"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63152-3"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)90000-2"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.115566"},{"key":"e_1_2_9_8_2","first-page":"1","article-title":"Allergen immunotherapy","volume":"53","author":"World_Health_Organization.","year":"1998","journal-title":"therapeutic vaccines for allergic diseases"},{"key":"e_1_2_9_9_2","first-page":"56","article-title":"Complexed flavonoids on pollen protein allergens revealed by UV\u2010spectroscopy and thin\u2010layer chromatography","volume":"53","author":"Berrens L","year":"1998","journal-title":"Allergy"},{"key":"e_1_2_9_10_2","first-page":"244","article-title":"Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerised extract of Dermatophagoides pteronyssinus and D. farinae","volume":"13","author":"Ferrer A","year":"2003","journal-title":"J Invest Allergol clin Immunol"},{"key":"e_1_2_9_11_2","first-page":"108","article-title":"Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens","volume":"13","author":"Guerra F","year":"2003","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_9_12_2","first-page":"325","article-title":"Immunotherapy with a standardized Dermatophagoides pteronyssinus glutaraldehyde\u2010modified extract against an unmodified extract","volume":"5","author":"Echechipia S","year":"1995","journal-title":"a comparative study of efficacy, tolerance and in vivo and in vitro modification of parameters"},{"key":"e_1_2_9_13_2","first-page":"226","article-title":"Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract","volume":"22","author":"Malet A","year":"1994","journal-title":"Allergol Immunolpathol (Madrid)"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70083-0"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.99.2.165"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70380-5"},{"key":"e_1_2_9_17_2","first-page":"1341","article-title":"Measuring health status","volume":"45","author":"Guyatt GH","year":"1992","journal-title":"what are the necessary measurement properties?"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70135-5"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0019-2791(70)90278-8"},{"key":"e_1_2_9_20_2","first-page":"207","article-title":"Determinations of Par j 1 by a competitive enzyme immunoassay using human specific IgE and IgG","volume":"8","author":"Boluda L","year":"1998","journal-title":"Validation by skin prick testing"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1994.tb00209.x"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1006\/biol.1994.1023"},{"key":"e_1_2_9_23_2","first-page":"556","article-title":"Monoclonal antibody\u2010standardized cat extract immunotherapy","volume":"93","author":"Alvarez\u2010Cuesta E","year":"1994","journal-title":"risk\u2013benefit effects from a double-blind placebo study"},{"issue":"14","key":"e_1_2_9_24_2","first-page":"48","article-title":"Position paper","volume":"48","author":"EAACI.","year":"1993","journal-title":"Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology"},{"key":"e_1_2_9_25_2","unstructured":"Nordic\u2010Council\u2010on\u2010Medicines Registration of allergen preparations. Nordic\u2010guidelines. Prepared by the Nordic Council on Medicines in cooperation with the Drug Regulatory Authorities in Denmark Finland Iceland Norway and Sweden. NLN Publication No. 23 January 1989: 1\u201336."},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1987.tb02368.x"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(95)70028-5"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-7348.1952.tb00904.x"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1986.tb00289.x"},{"key":"e_1_2_9_30_2","first-page":"148","article-title":"Clinically important differences in health\u2010related quality of life for patients with asthma","volume":"91","author":"Kathleen WW","year":"2003","journal-title":"an expert consensus panel report"},{"key":"e_1_2_9_31_2","first-page":"225","article-title":"Comparison of powder and aerosolised budesonide in perennial rhinitis","volume":"70","author":"Juniper EF","year":"1994","journal-title":"validation of rhinitis quality of life questionnaire"},{"key":"e_1_2_9_32_2","first-page":"66","article-title":"Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration","volume":"10","author":"Burtin B","year":"2000","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_9_33_2","first-page":"3","article-title":"Aqueous beclomethosone diproprionate nasal spray","volume":"86","author":"Juniper EF","year":"1990","journal-title":"regular versus \u2018as required\u2019 use in the treatment of seasonal allergic rhinitis"},{"key":"e_1_2_9_34_2","first-page":"115","article-title":"Interpreting quality of life data","volume":"91","author":"Juniper EF.","year":"2003","journal-title":"should we listen to the patient or the clinician?"},{"issue":"14","key":"e_1_2_9_35_2","first-page":"7","article-title":"Position paper","volume":"48","author":"EAACI_Immunotherapy_Subcommittee.","year":"1993","journal-title":"immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology"},{"key":"e_1_2_9_36_2","volume-title":"Statistical Methods in Biological Assay","author":"Finney DJ.","year":"1964"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540080059030"},{"key":"e_1_2_9_38_2","first-page":"87","article-title":"Grass pollen immunotherapy for seasonal rhinitis and asthma","volume":"107","author":"Walker SM","year":"2001","journal-title":"a randomized, controlled trial"},{"key":"e_1_2_9_39_2","first-page":"45","article-title":"Clinical efficacy of sublingual and subcutaneous birch pollen allergen\u2010specific immunotherapy","volume":"59","author":"Khinchi MS","year":"2004","journal-title":"a randomised, placebo-controlled, double-blind, double-dummy study"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119090-00001"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.1o3306.x"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701303360502"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2005.02245.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2005.02245.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T10:14:15Z","timestamp":1697364855000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2005.02245.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1365-2222.2005.02245.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2005.02245.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}